The Antitumor Effects of CIK Cells Combined with Docetaxel Against Drug-Resistant Lung Adenocarcinoma Cell Line SPC-A1/DTX in Vitro and in Vivo
The Antitumor Effects of CIK Cells Combined with Docetaxel Against Drug-Resistant Lung Adenocarcinoma Cell Line SPC-A1/DTX in Vitro and in Vivo
复制标题
DOI：
10.1089/cbr.2008.0533
复制
发表时间：
2009-02-01
影响因子：
3.4
通讯作者：
Huang, Xiang
中科院分区：
文献类型：
--
作者：
Liu, Pengying;Chen, Longbang;Huang, Xiang
目的：本研究旨在探讨细胞因子诱导杀伤（CIK）细胞联合多西紫杉醇（DTX）对耐药肺腺癌细胞株SPC-A1/DTX体内外生长的抑制作用。方法：采用MTT法评价DTX、CIK细胞以及DTX+CIK细胞对SPC-A1/DTX细胞的体外细胞毒活性。在体内实验中，将SPC-A1/DTX细胞皮下注射到裸鼠体内，建立荷瘤小鼠模型。第14天，分别腹腔注射生理盐水、多西他赛、CIK细胞、CIK细胞联合多西他赛。治疗后第15天处死所有裸鼠并称出肿瘤重量。结果：MTT法显示CIK细胞对SPC-A1/DTX细胞的体外抗肿瘤细胞毒活性高于SPC-A1细胞（p < 0.05）。协同抗肿瘤活性与E:T比值和多西紫杉醇的浓度呈正相关。动物数据还表明，CIK细胞与DTX联合对体内肿瘤生长具有更强的抑制作用。结论：CIK细胞联合多西紫杉醇在体外和体内均表现出对多药耐药肺腺癌细胞系的抗肿瘤活性显着增强。
Objective: The aim of this study was to investigate the inhibitory effects of cytokine-induced killer (CIK) cells combined with docetaxel (DTX) on the growth of drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Methods: The MTT assay was employed to evaluate the cytotoxic activity of DTX, CIK cells, and DTX plused CIK cells against SPC-A1/DTX cells in vitro. For the in vivo assay, SPC-A1/DTX cells were injected into nude mice subcutaneously to establish a tumor-bearing mice model. On the day 14, normal saline, docetaxel, CIK cells, and CIK cells combined with docetaxel were administered intraperitoneally, respectively. All the nude mice were sacrificed at day 15 after treatment and the tumors were weighed out. Results: The MTT assay showed that CIK cells possessed a higher antitumor cytotoxic activity against SPC-A1/DTX cells than SPC-A1 cells in vitro (p < 0.05). The synergetic antitumor activity positively correlated with the E:T ratio and the concertration of docetaxel. The animal data also suggested that CIK cells combined with DTX had a stronger suppressive effect on tumor growth in vivo. Conclusion: CIK cells plused with docetaxel demonstrated a prominent augmentation of antitumor activity against multidrug resistance lung adenocarcinoma cell lines both in vitro and in vivo.